Stephen B. Heitner, MD

Cardiologist • Clinical Researcher • Drug Development Leader
Focused on advancing therapies in hypertrophic cardiomyopathy and heart failure, bridging academic medicine, clinical trials, and industry leadership.
Cardiovascular Drug Development
Hypertrophic Cardiomyopathy
Heart Failure
Muscle Biology
SH
Contact
Email: sheitner@cytokinetics.com
LinkedIn: LinkedIn Profile
Company: Cytokinetics Profile
Location: Portland, Oregon, USA

About

Stephen B. Heitner, MD is a cardiologist and clinical investigator with experience spanning academic medicine, cardiovascular imaging, and late-stage drug development in heart failure and hypertrophic cardiomyopathy.

Selected Publications

  • Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM)
    New England Journal of Medicine • 2024 • NEJM
  • Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy (MAPLE-HCM)
    New England Journal of Medicine • 2025 • NEJM
  • Additional publications and abstracts in cardiomyopathy, heart failure, and muscle biology.
    Google Scholar • PubMed Search

Clinical & Research Focus

  • Therapeutic Areas
    Hypertrophic cardiomyopathy (HCM), heart failure, cardiomyopathies, muscle biology, and inherited cardiovascular disease.
  • Clinical Trial Design Expertise
    Phase 1, 2, 3, and 4 clinical trials, including endpoint selection, exercise testing, imaging-based measures, and patient-reported outcomes.

Links

Keynote & panel speaking
Cardiovascular trials
HCM & HF
Fixed